Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
In Vitro Release of SM-11355, cis[((1R, 2R)-1, 2-Cyclohexanediamine-N, N')bis(myristato)]Platinum(II) Suspended in Lipiodol
Shuichi KISHIMOTOToshihiro NOGUCHITakashi YAMAOKASHoji FUKUSHIMAYoshikazu TAKEUCHI
Author information
JOURNAL FREE ACCESS

2000 Volume 23 Issue 5 Pages 637-640

Details
Abstract

SM-11355, cis[((1R, 2R)-1, 2-cyclohexanediamine-N, N')bis(myristato)] platinum(II) is a lipophilic platinum complex. SM-11355 suspended in Lipiodol (SM-11355/Lipiodol) was previously shown to have antitumor effects against rat hepatic tumors after intra-arterial administration. In the present study, the in vitro release of platinum compounds from SM-11355/Lipiodol was examined. A test tube containing 10 ml of saline and 1 ml of SM-11355/Lipiodol was rotated at 5 rmp in a vertical orientation. The platinum concentration in saline gradually increased for 28 d. From HPLC analysis, cyclohexane-1, 2-diamineplatinum(II) dichloride (DPC) and cyclohexane-1, 2-diamineplatinum(II) chloroiodide (DPCI) were detected in the saline, and the sum of these two compounds was equivalent to the total platinum amount in the saline determined by atomic absorption spectrophotometry at days 21 and 28. DPC showed significant growth inhibitory activities, with IC50 values of 0.1-0.7 nmol/ml in rat hepatoma AH-109A cells and 5 human tumor cell lines, as effective as cisplatin. These findings suggest that SM-11355/Lipipdol exerts antitumor effects by releasing active platinum compounds, and that DPC is one of the candidates of the active compounds.

Content from these authors
© The Pharmaceutical Society of Japan
Previous article Next article
feedback
Top